↧
Roundtable: Two Trials, Two Anticoagulants, Many Implications
After findings from the industry-funded ATLAS ACS 2–TIMI 51 and ADOPT trials were presented at AHA and published in the New England Journal of Medicine, CardioExchange asked three experts to weigh in....
View ArticleRevisiting Novel Anticoagulants in Atrial Fibrillation
With all that’s changed in the swiftly evolving world of novel anticoagulants, we invited Christian Thomas Ruff, MD, MPH, and Andrew E. Epstein, MD to answer our questions—and yours—on the use of these...
View ArticleEdoxaban and the Changing Landscape of Novel Anticoagulants for Atrial...
CardioExchange’s John Ryan interviews Christian Thomas Ruff, a coauthor of the ENGAGE AF-TIMI 48 trial of edoxaban versus warfarin in patients with atrial fibrillation. The study was published in The...
View Article